Categorization of Cytochrome P4502D6 Activity Score by Urinary Amphetamine/Methamphetamine Ratios
Abstract
:1. Introduction
2. Materials and Methods
2.1. Chemicals and Materials
2.2. Standard Solutions and Quality Controls Preparation
2.3. Method Validation
2.4. SPME GC–NPD Condition
2.5. Urine Samples Collection
2.6. Determination of Methamphetamine and Amphetamine Levels
2.7. Estimation of a Relative Location of the CYP2D6 Activity Score
2.8. Statistical Analysis
3. Results
3.1. Method Validation
3.2. Urinary Methamphetamine and Amphetamine Data
3.3. Categorization of the CYP2D6 Activity Score in the Population
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Zanger, U.M.; Fischer, J.; Raimundo, S.; Stüven, T.; Evert, B.O.; Schwab, M.; Eichelbaum, M. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharm. Genom. 2001, 11, 573–585. [Google Scholar] [CrossRef] [PubMed]
- Owen, R.P.; Sangkuhl, K.; Klein, T.E.; Altman, R.B. Cytochrome P450 2D6. Pharm. Genom. 2009, 19, 559. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Marcucci, K.A.; Pearce, R.E.; Crespi, C.; Steimel, D.T.; Leeder, J.S.; Gaedigk, A. Characterization of cytochrome P450 2D6. 1 (CYP2D6. 1), CYP2D6. 2, and CYP2D6. 17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine. Drug Metab. Dispos. 2002, 30, 595–601. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ning, M.; Duarte, J.D.; Rubin, L.H.; Jeong, H. CYP2D6 protein level is the major contributor to interindividual variability in CYP2D6-mediated drug metabolism in healthy human liver tissue. Clin. Pharmacol. Ther. 2018, 104, 974–982. [Google Scholar] [CrossRef] [PubMed]
- Gaedigk, A.; Simon, S.D.; Pearce, R.E.; Bradford, L.D.; Kennedy, M.J.; Leeder, J.S. The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther. 2008, 83, 234–242. [Google Scholar] [CrossRef] [PubMed]
- Molden, E.; Jukic, M.M. CYP2D6 Reduced Function Variants and Genotype/Phenotype Translations of CYP2D6 Intermediate Metabolizers: Implications for Personalized Drug Dosing in Psychiatry. Front. Pharmacol. 2021, 12, 650750. [Google Scholar] [CrossRef]
- Alali, M.; Ismail Al-Khalil, W.; Rijjal, S.; Al-Salhi, L.; Saifo, M.; Youssef, L.A. Frequencies of CYP2D6 genetic polymorphisms in Arab populations. Hum. Genomics. 2022, 16, 6. [Google Scholar] [CrossRef] [PubMed]
- Li, Q.; Wu, Y.E.; Wang, K.; Shi, H.Y.; Zhou, Y.; Zheng, Y.; Hao, G.X.; Yang, Y.L.; Su, L.Q.; Wang, W.Q.; et al. Developmental Pharmacogenetics of CYP2D6 in Chinese Children: Loratadine as a Substrate Drug. Front. Pharmacol. 2021, 12, 657287. [Google Scholar] [CrossRef] [PubMed]
- Miranda, G.E.; Sordo, M.; Salazar, A.M.; Contreras, C.; Bautista, L.; Rojas Garcia, A.E.; Ostrosky-Wegman, P. Determination of amphetamine, methamphetamine, and hydroxyamphetamine derivatives in urine by gas chromatography-mass spectrometry and its relation to CYP2D6 phenotype of drug users. J. Anal. Toxicol. 2007, 31, 31–36. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chladek, J.; Zimova, G.; Beranek, M.; Martinkova, J. In-vivo indices of CYP2D6 activity: Comparison of dextromethorphan metabolic ratios in 4-h urine and 3-h plasma. Eur. J. Clin. Pharmacol. 2000, 56, 651–657. [Google Scholar] [CrossRef] [PubMed]
- Tay-Sontheimer, J.; Shireman, L.M.; Beyer, R.P.; Senn, T.; Witten, D.; Pearce, R.E.; Gaedigk, A.; Gana Fomban, C.L.; Lutz, J.D.; Isoherranen, N.; et al. Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics. Pharmacogenomics 2014, 15, 1947–1962. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hongkaew, Y.; Gaedigk, A.; Wilffert, B.; Ngamsamut, N.; Kittitharaphan, W.; Limsila, P.; Sukasem, C. Relationship between CYP2D6 genotype, activity score and phenotype in a pediatric Thai population treated with risperidone. Sci. Rep. 2021, 11, 4158. [Google Scholar] [CrossRef] [PubMed]
- Darney, K.; Lautz, L.; Béchaux, C.; Wiecek, W.; Testai, E.; Amzal, B.; Dorne, J. Human variability in polymorphic CYP2D6 metabolism: Implications for the risk assessment of chemicals in food and emerging designer drugs. Environ. Int. 2021, 156, 106760. [Google Scholar] [CrossRef] [PubMed]
- Jukic, M.M.; Smith, R.L.; Molden, E.; Ingelman-Sundberg, M. Evaluation of the CYP2D6 Haplotype Activity Scores Based on Metabolic Ratios of 4,700 Patients Treated with Three Different CYP2D6 Substrates. Clin. Pharmacol. Ther. 2021, 110, 750–758. [Google Scholar] [CrossRef] [PubMed]
- German, D.; Sherman, S.G.; Sirirojn, B.; Thomson, N.; Aramrattana, A.; Celentano, D.D. Motivations for methamphetamine cessation among young people in northern Thailand. Addiction 2006, 101, 1143–1152. [Google Scholar] [CrossRef] [PubMed]
- Cherner, M.; Bousman, C.; Everall, I.; Barron, D.; Letendre, S.; Vaida, F.; Atkinson, J.H.; Heaton, R.; Grant, I.; Group, H. Cytochrome P450-2D6 extensive metabolizers are more vulnerable to methamphetamine-associated neurocognitive impairment: Preliminary findings. J. Int. Neuropsychol. Soc. 2010, 16, 890–901. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jiao, D.; Liu, Y.; Li, X.; Liu, J.; Zhao, M. The role of the GABA system in amphetamine-type stimulant use disorders. Front. Cell Neurosci. 2015, 9, 162. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kish, S.J.; Fitzmaurice, P.S.; Boileau, I.; Schmunk, G.A.; Ang, L.C.; Furukawa, Y.; Chang, L.J.; Wickham, D.J.; Sherwin, A.; Tong, J. Brain serotonin transporter in human methamphetamine users. Psychopharmacology 2009, 202, 649–661. [Google Scholar] [CrossRef] [PubMed]
- Kim, B.; Yun, J.; Park, B. Methamphetamine-Induced Neuronal Damage: Neurotoxicity and Neuroinflammation. Biomol. Ther. 2020, 28, 381–388. [Google Scholar] [CrossRef]
- Baucum, A.J., 2nd; Rau, K.S.; Riddle, E.L.; Hanson, G.R.; Fleckenstein, A.E. Methamphetamine increases dopamine transporter higher molecular weight complex formation via a dopamine- and hyperthermia-associated mechanism. J. Neurosci. 2004, 24, 3436–3443. [Google Scholar] [CrossRef] [PubMed]
- Li, L.; Everhart, T.; Jacob Iii, P.; Jones, R.; Mendelson, J. Stereoselectivity in the human metabolism of methamphetamine. Br. J. Clin. Pharmacol. 2010, 69, 187–192. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Otani, K.; Ujike, H.; Sakai, A.; Okahisa, Y.; Kotaka, T.; Inada, T.; Harano, M.; Komiyama, T.; Hori, T.; Yamada, M.; et al. Reduced CYP2D6 activity is a negative risk factor for methamphetamine dependence. Neurosci. Lett. 2008, 434, 88–92. [Google Scholar] [CrossRef] [PubMed]
- Kaza, M.; Karazniewicz-Lada, M.; Kosicka, K.; Siemiatkowska, A.; Rudzki, P.J. Bioanalytical method validation: New FDA guidance vs. EMA guideline. Better or worse? J. Pharm. Biomed. Anal. 2019, 165, 381–385. [Google Scholar] [CrossRef] [PubMed]
- Kanamori, T.; Tsujikawa, K.; Ohmae, Y.; Iwata, Y.T.; Inoue, H.; Kishi, T.; Nakahama, T.; Inouye, Y. A study of the metabolism of methamphetamine and 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in isolated rat hepatocytes. Forensic. Sci. Int. 2005, 148, 131–137. [Google Scholar] [CrossRef] [PubMed]
- Williams, I.S.; Gatchie, L.; Bharate, S.B.; Chaudhuri, B. Biotransformation, Using Recombinant CYP450-Expressing Baker’s Yeast Cells, Identifies a Novel CYP2D6.10(A122V) Variant Which Is a Superior Metabolizer of Codeine to Morphine Than the Wild-Type Enzyme. ACS Omega 2018, 3, 8903–8912. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nofziger, C.; Turner, A.J.; Sangkuhl, K.; Whirl-Carrillo, M.; Agundez, J.A.G.; Black, J.L.; Dunnenberger, H.M.; Ruano, G.; Kennedy, M.A.; Phillips, M.S.; et al. PharmVar GeneFocus: CYP2D6. Clin. Pharmacol. Ther. 2020, 107, 154–170. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Taylor, C.; Crosby, I.; Yip, V.; Maguire, P.; Pirmohamed, M.; Turner, R.M. A Review of the Important Role of CYP2D6 in Pharmacogenomics. Genes 2020, 11, 1295. [Google Scholar] [CrossRef]
- Lesche, D.; Mostafa, S.; Everall, I.; Pantelis, C.; Bousman, C.A. Impact of CYP1A2, CYP2C19, and CYP2D6 genotype-and phenoconversion-predicted enzyme activity on clozapine exposure and symptom severity. Pharm. J. 2020, 20, 192–201. [Google Scholar] [CrossRef] [PubMed]
- Yao, T.W.; Zeng, S.; Wang, T.W.; Chen, S.Q. Phenotype analysis of cytochrome P450 2C19 in Chinese subjects with mephenytoin S/R enantiomeric ratio in urine measured by chiral GC. Biomed. Chromatogr. 2001, 15, 9–13. [Google Scholar] [CrossRef] [PubMed]
- de la Torre, R.; Yubero-Lahoz, S.; Pardo-Lozano, R.; Farre, M. MDMA, methamphetamine, and CYP2D6 pharmacogenetics: What is clinically relevant? Front. Genet 2012, 3, 235. [Google Scholar] [CrossRef]
- He, Y.J.; Brockmoller, J.; Schmidt, H.; Roots, I.; Kirchheiner, J. CYP2D6 ultrarapid metabolism and morphine/codeine ratios in blood: Was it codeine or heroin? J. Anal. Toxicol. 2008, 32, 178–182. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lutz, U.; Volkel, W.; Lutz, R.W.; Lutz, W.K. LC-MS/MS analysis of dextromethorphan metabolism in human saliva and urine to determine CYP2D6 phenotype and individual variability in N-demethylation and glucuronidation. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2004, 813, 217–225. [Google Scholar] [CrossRef] [PubMed]
- Cunningham, J.K.; Liu, L.M.; Muramoto, M. Methamphetamine suppression and route of administration: Precursor regulation impacts on snorting, smoking, swallowing and injecting. Addiction 2008, 103, 1174–1186. [Google Scholar] [CrossRef] [PubMed]
- Gupta, M.; Bailey, S.; Lovato, L.M. Bottoms up: Methamphetamine toxicity from an unusual route. West J. Emerg. Med. 2009, 10, 58–60. [Google Scholar] [PubMed]
- Le Bourdonnec, B.; Leister, L.K. Medicinal chemistry strategies to reduce CYP2D6 inhibitory activity of lead candidates. Curr. Med. Chem. 2009, 16, 3093–3121. [Google Scholar] [CrossRef] [PubMed]
- Yasuda, K.; Ikushiro, S.; Kamakura, M.; Ohta, M.; Sakaki, T. Metabolism of sesamin by cytochrome P450 in human liver microsomes. Drug Metab. Dispos. 2010, 38, 2117–2123. [Google Scholar] [CrossRef] [Green Version]
- Sasaki, T.; Sato, Y.; Kumagai, T.; Yoshinari, K.; Nagata, K. Effect of health foods on cytochrome P450-mediated drug metabolism. J. Pharm. Health Care Sci. 2017, 3, 14. [Google Scholar] [CrossRef] [PubMed]
- Labbe, L.; Sirois, C.; Pilote, S.; Arseneault, M.; Robitaille, N.M.; Turgeon, J.; Hamelin, B.A. Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates. Pharmacogenetics 2000, 10, 425–438. [Google Scholar] [CrossRef]
Quality Controls Concentration (μg/mL) | Concentration Mean ± SD (μg/mL) | Precision CV (%) | Accuracy RD (%) | |||
---|---|---|---|---|---|---|
MA | AM | MA | AM | MA | AM | |
Within-run (n = 5) | ||||||
| 0.82 ± 0.01 | 0.80 ± 0.01 | 0.8 | 0.8 | 8.4 | 9.8 |
| 1.52 ± 0.04 | 1.48 ± 0.05 | 2.0 | 3.2 | −0.3 | −0.3 |
| 3.02 ± 0.05 | 3.01 ± 0.06 | 3.5 | 1.7 | −0.4 | 0.0 |
Between-run (n = 15) | ||||||
| 0.84 ± 0.02 | 0.81 ± 0.01 | 2.3 | 1.7 | 11.3 | 11.3 |
| 1.56 ± 0.05 | 1.50 ± 0.07 | 3.1 | 4.8 | 2.4 | 1.4 |
| 3.12 ± 0.13 | 3.10 ± 0.17 | 4.3 | 5.6 | 1.6 | 4.5 |
Concentration (µg/mL) | Male (n = 15,656) | Female (n = 1484) |
---|---|---|
Methamphetamine | 29.38 ± 52.76 | 26.55 ± 31.95 |
99% CI of MA | 28.29–30.46 | 24.42–28.69 |
Min-Max value of MA | 0.01–2603.73 | 0.12–351.19 |
Amphetamine | 4.34 ± 16.34 | 4.35 ± 14.78 |
99% CI of AM | 4.01–4.68 | 3.36–5.34 |
Min-Max value of AM | 0.02–677.14 | 0.05–305.31 |
Positions | CYP2D6 Activity Score (×10−1) | Number | 99% CI for Mean Activity Score | Range of CYP2D6 Activity Score |
---|---|---|---|---|
<2.5th | <0.24 | 393 | 0.012–0.013 | 2.51 × 10−4–2.42 × 10−2 |
2.5th–50th | 0.24–1.41 | 7437 | 0.087–0.088 | 2.42 × 10−2–0.14 |
50th–97.5th | 1.41–8.36 | 7435 | 0.232–0.236 | 0.14–0.84 |
>97.5th | >8.36 | 391 | 2.443–3.090 | 0.84–530.36 |
Positions | CYP2D6 Activity Score (×10−1) | Number | 99% CI for Mean Activity Score | Range of CYP2D6 Activity Score |
---|---|---|---|---|
<2.5th | <0.23 | 37 | 0.011–0.015 | 2.96 × 10−3–2.23 × 10−2 |
2.5th–50th | 0.23–1.48 | 705 | 0.091–0.096 | 2.58 × 10−2–0.15 |
50th–97.5th | 1.48–8.50 | 705 | 0.228–0.241 | 0.15–0.84 |
>97.5th | >8.50 | 37 | 2.539–4.825 | 0.85–25.89 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Chaichana, J.; Khamenkhetkarn, M.; Sastraruji, T.; Monum, T.; O’Brien, T.E.; Amornlertwatana, Y.; Jaikang, C. Categorization of Cytochrome P4502D6 Activity Score by Urinary Amphetamine/Methamphetamine Ratios. Metabolites 2022, 12, 1174. https://doi.org/10.3390/metabo12121174
Chaichana J, Khamenkhetkarn M, Sastraruji T, Monum T, O’Brien TE, Amornlertwatana Y, Jaikang C. Categorization of Cytochrome P4502D6 Activity Score by Urinary Amphetamine/Methamphetamine Ratios. Metabolites. 2022; 12(12):1174. https://doi.org/10.3390/metabo12121174
Chicago/Turabian StyleChaichana, Jatuporn, Manee Khamenkhetkarn, Thanapat Sastraruji, Tawachai Monum, Timothy E. O’Brien, Yutti Amornlertwatana, and Churdsak Jaikang. 2022. "Categorization of Cytochrome P4502D6 Activity Score by Urinary Amphetamine/Methamphetamine Ratios" Metabolites 12, no. 12: 1174. https://doi.org/10.3390/metabo12121174